Skip to content

Study of efficiency optimization and safety of GnRH-antagonist ovarian stimulation in IVF

Study of efficiency optimization and safety of GnRH-antagonist ovarian stimulation in IVF

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041692
Enrollment
Unknown
Registered
2021-01-01
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Normal ovarian response stimulated by GnRH-antagonist protocol group:Controlled ovarian stimulation was performed using GnRH antagonist protocol
Normal ovarian response stimulated by GnRH agonist long protocol group:Controlled ovarian stimulation was performed using GnRH agonist long protocol
High ovarian response stimulated by GnRH-antagonist protocol group:Controlled ovarian stimulation was performed using GnRH antagonist protocol
High ovarian response stimulated by GnRH agonist long protocol group:Controlled ovarian stimulation was performed using GnRH agonist long protocol
Poor ovarian response stimulated by GnRH-antagonist protocol group:Controlled ovarian stimulation was performed using GnRH antagonist protocol
Poor ovarian response stimulated by GnRH agonist long protocol group:Controlled ovarian stimulation was performed using GnRH agonist long protocol

Sponsors

Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Meet the indications for in vitro fertilization treatment; 2. Women's aged 20 to 45 years.

Exclusion criteria

Exclusion criteria: 1. There are contraindications for in vitro fertilization; 2. Chromosome abnormality in one of them; 3. The woman has stage III to IV endometriosis or adenomyosis; 4. The woman has no operation history of ovarian tumor in recent half a year, and has no history of pelvic radiotherapy and chemotherapy in recent half a year; 5. The patient has hydrosalpinx without tubal ligation or resection; and 6. Women have severe endometrial lesions(intrauterine adhesions, semen Abnormal endometrium); 7. Severe oligozoospermia and asthenospermia; 8. BMI 26 kg/m2.

Design outcomes

Primary

MeasureTime frame
cumulative live birth rate;

Secondary

MeasureTime frame
OHSS rate;Freezing all embryo rate;embryo freezing rate;Cycle cancellation rate;mean number of transplanted embryos;Number of embryos available;The total Gn dose;Duration of Gn stimulation;No. of oocytes retrieved;normal fertilization rate;

Countries

China

Contacts

Public ContactHong Zhou

Reproductive Center of Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region

zhouhh2009@126.com+86 13768270781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026